News After CagriSema blow, Novo reveals data for obesity 'triple' Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
R&D Searching for new weight loss treatments Using IP intelligence to guide R&D activity can also help companies to develop treatments that are more effective, with fewer side effects.
Patients Tackling inappropriate prescription practices for weight los... A critical issue within the pharmaceutical sector has been highlighted by the MHRA’s investigation into the improper prescription of Wegovy.
Market Access Weighing the pros and cons, and dollars and cents, of the ne... Obesity rates in the United States have tripled since the 1980s. According to the CDC, a mind-boggling 41.9% of adults were obese as of 2020.
Market Access Are we entering a new era of blockbuster weight-loss drugs? Has the industry found a new revenue driver in weight-loss treatments?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.